Investigación local. Conexiones humanas. WCR Miami Lakes (786) 483-7856
Volver a buscar estudiosNCT07929090
ReclutandoNCT07929090Registro de ClinicalTrials.gov

Pectoral Nerve Block Versus Serratus Posterior Superior Intercostal Plane Block for Pain Control After Mastectomy

Postoperative Pain · Breast Cancer · Persistent Postsurgical Pain

LO ESENCIAL

De qué trata este estudio

El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.

Tipo de estudio
De intervención
Fase
No aplica
Rango de edad
18 años - 85 años
Sexo admitido
Femenino
Voluntarios sanos
No aceptados
Participantes
78 Estimado

Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.

Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.

Acerca de la investigación

This study compares two ultrasound-guided nerve block techniques for pain control after mastectomy for breast cancer: the pectoral nerve block (PECS II) and the serratus posterior superior intercostal plane (SPSIP) block. Both techniques involve injecting local anesthetic near nerves supplying the surgical area.

The study will include 78 adults aged 18 to 85 years undergoing elective mastectomy under general anesthesia. Participants will be randomly assigned to receive one of the two blocks before surgery. Both groups will receive postoperative pain treatment, including a patient-controlled device that delivers tramadol when needed.

The main aim is to compare postoperative opioid consumption. The study will also assess pain at rest and during movement, the need for additional pain medication, side effects, recovery quality, and persistent pain. Pain scores and tramadol consumption will be recorded at 0, 2, 4, 8, 16, and 24 hours after surgery. Recovery quality will be assessed at 24 hours, and persistent pain will be assessed by telephone at 3 months.

Leer la descripción completa

This prospective, randomized study will be conducted at Bursa City Hospital in adults undergoing elective mastectomy for breast cancer. Participants will be assigned to an ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block or a pectoral nerve block (PECS II) using a computer-generated randomization sequence.

Both blocks will be performed before induction of general anesthesia. The SPSIP group will receive 30 mL of 0.25% bupivacaine in the fascial plane between the serratus posterior superior and intercostal muscles at the third rib. The PECS II group will receive 10 mL of 0.25% bupivacaine between the pectoralis major and pectoralis minor muscles and 20 mL between the pectoralis minor and serratus anterior muscles.

General anesthesia and postoperative multimodal analgesia will be standardized. On arrival in the recovery room, participants will receive intravenous patient-controlled analgesia with tramadol at a concentration of 5 mg/mL, a bolus dose of 10 mg, a lockout interval of 20 minutes, and no basal infusion. Intravenous meperidine at 0.5 mg/kg will be administered as rescue analgesia when the Numeric Rating Scale (NRS) score is 4 or higher.

Postoperative pain and opioid consumption will be assessed by an anesthesiologist who is unaware of group allocation. The clinician performing the block will know the assigned technique and will not collect postoperative outcome data.

NRS scores at rest and during movement will be recorded at 0, 2, 4, 8, 16, and 24 hours after surgery. The scale ranges from 0 (no pain) to 10 (the worst pain imaginable). Tramadol consumption will be recorded at the same time points. Rescue analgesic requirements, time to first rescue analgesia, time to first postoperative mobilization, length of hospital stay, adverse effects, and block-related complications will also be recorded.

Quality of recovery will be assessed using the Quality of Recovery-15 questionnaire at 24 hours after surgery. Postoperative nausea and vomiting will be monitored during the first 24 hours. Persistent postoperative pain will be assessed at 3 months using the McGill Pain Questionnaire during a telephone interview conducted with prior participant consent.

¿Quién podría participar?

La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.

Inclusion Criteria:

  • Age between 18 and 85 years.
  • Scheduled for elective mastectomy for breast cancer under general anesthesia.
  • American Society of Anesthesiologists (ASA) physical status I, II, or III.
  • Willingness to participate in the study and provide informed consent.

Exclusion Criteria:

  • Refusal to participate in the study.
  • History of bleeding diathesis or coagulopathy.
  • Receiving anticoagulant therapy.
  • Allergy or hypersensitivity to local anesthetics or opioid medications.
  • History of local anesthetic toxicity.
  • Infection at the planned block injection site.
  • Hepatic or renal failure.
  • Uncontrolled diabetes mellitus.
  • Uncontrolled hypertension.
  • Intellectual disability.
  • Receiving opioid treatment for chronic pain.
  • Pregnancy, suspected pregnancy, or breastfeeding.
  • Planned bilateral mastectomy.
Entiende la evaluación inicial

Tratamiento, grupos y participación

El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.

Asignación
Asignación al azar
Enmascaramiento
Enmascaramiento simple
Serratus Posterior Superior Intercostal Plane Block (SPSIP)

Participants will receive an ultrasound-guided SPSIP block on the surgical side before induction of general anesthesia. With the participant seated, 30 mL of 0.25% bupivacaine with epinephrine will be injected into the fascial plane between the serratus posterior superior and intercostal muscles at the third rib. Participants will also receive standardized general anesthesia and postoperative multimodal analgesia, including patient-controlled intravenous tramadol and rescue analgesia when required.

Other: Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block

Pectoral Nerve Block (PECS II)

Participants will receive an ultrasound-guided PECS II block on the surgical side before induction of general anesthesia. With the participant supine, 10 mL of 0.25% bupivacaine with epinephrine will be injected between the pectoralis major and pectoralis minor muscles, followed by 20 mL between the pectoralis minor and serratus anterior muscles. Participants will also receive standardized general anesthesia and postoperative multimodal analgesia, including patient-controlled intravenous tramadol and rescue analgesia when required.

Other: Ultrasound-Guided Pectoral Nerve Block Type II

Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block OTHER

A single ultrasound-guided block will be performed on the surgical side before induction of general anesthesia. With the participant seated and the hand on the opposite shoulder, a high-frequency linear ultrasound probe will be positioned along the medial scapular border to identify the third rib and serratus posterior superior muscle. A 50-mm block needle will be advanced in-plane in a caudal-to-cranial direction. After confirming the plane with 5 mL of saline, 30 mL of 0.25% bupivacaine with epinephrine will be injected between the serratus posterior superior and intercostal muscles.

Ultrasound-Guided Pectoral Nerve Block Type II OTHER

A single ultrasound-guided PECS II block will be performed on the surgical side before induction of general anesthesia, with the participant supine. A high-frequency linear ultrasound probe will be used to identify the pectoralis major, pectoralis minor, and serratus anterior muscles. A 50-mm block needle will be advanced using an in-plane approach. After confirming each injection plane with 5 mL of saline, 10 mL of 0.25% bupivacaine with epinephrine will be injected between pectoralis major and pectoralis minor, followed by 20 mL of the same solution between pectoralis minor and serratus anterior.

Prepara tus preguntas

Qué evalúan los investigadores

Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.

Medidas principales

Postoperative Opioid Consumption

Plazo: First 24 hours postoperatively, with recordings at 0, 2, 4, 8, 16, and 24 hours.

Postoperative opioid consumption will be compared between the groups. Tramadol consumption administered through intravenous patient-controlled analgesia will be recorded in milligrams at 0, 2, 4, 8, 16, and 24 hours postoperatively. The total dose of rescue meperidine will be recorded separately.

Medidas secundarias

Pain Intensity at Rest

Plazo: At 0, 2, 4, 8, 16, and 24 hours postoperatively.

Pain intensity at rest will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity.

Pain Intensity During Movement

Plazo: At 0, 2, 4, 8, 16, and 24 hours postoperatively.

Pain intensity during movement will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity.

Total Rescue Analgesic Dose

Plazo: During the first 24 hours postoperatively.

The total dose of intravenous meperidine administered as rescue analgesia will be recorded in milligrams. Meperidine at 0.5 mg/kg will be administered when the Numeric Rating Scale score is 4 or higher.

Time to First Rescue Analgesia

Plazo: During the first 24 hours postoperatively.

The time of the first postoperative administration of rescue analgesia will be recorded. Intravenous meperidine at 0.5 mg/kg will be administered when the Numeric Rating Scale score is 4 or higher.

Quality of Recovery-15 Score

Plazo: At 24 hours postoperatively.

Quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The questionnaire contains 15 items, with a total score ranging from 0 to 150. Higher scores indicate better quality of recovery.

Postoperative Nausea and Vomiting

Plazo: During the first 24 hours postoperatively.

Postoperative nausea and vomiting will be assessed using a four-category scale: 1 = no nausea or vomiting; 2 = nausea without vomiting; 3 = one episode of vomiting or persistent nausea; and 4 = two or more episodes of vomiting or severe/persistent retching. Higher scores indicate more severe symptoms.

Persistent Postoperative Pain Assessed Using the McGill Pain Questionnaire

Plazo: At 3 months postoperatively.

Persistent postoperative pain will be assessed using the McGill Pain Questionnaire during a telephone interview at 3 months after surgery. Participants will provide prior consent for telephone follow-up.

El registro no indica resultados publicados.

Revisa las tablas completas y sus limitaciones en el registro oficial.

Abrir resultados oficiales ↗

Centros de investigación (1)

El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.

1 centros

Bursa City HospitalNilufer, Bursa, Turkey (Türkiye)Reclutando

Equipo y fechas

Patrocinador principal
Bursa City Hospital
Inicio del estudio
1 nov 2026 Real
Finalización primaria
15 jun 2027 Estimado
Finalización del estudio
15 jun 2027 Estimado
Primera publicación
10 nov 2026 Real
Última actualización
10 nov 2026 Real

Contactos oficiales del estudio

Enes Batuhan Cansız, MDCONTACTenbatuca55@gmail.com05384600660
Título oficial del estudio

Comparison of the Effects of Pectoral Nerve Block and Serratus Posterior Superior Intercostal Plane Block on Acute and Persistent Postoperative Pain After Mastectomy: A Prospective, Double-Blind, Randomized Controlled Trial

EL PRÓXIMO PASO, CON APOYO HUMANO

Consulta a Wellness Clinical Research

Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.

No incluyas expedientes médicos, diagnósticos, medicamentos, números de seguro ni otros datos sensibles. Este formulario es para preguntas generales, no para atención urgente.

Enviar una pregunta no te inscribe en un estudio.

Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.

Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026